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Background: Cervical cancer is the most prevalent gynaecologic cancer in Nigeria.
Despite being largely preventable through screening, cervical cancer is the second
leading cause of cancer morbidity and mortality in Nigeria. To reduce the burden of
cervical cancer in Nigeria, female health workers (FHWs) are expected to play an
influential role in leading screening uptake and promoting access to cervical cancer
education and screening.
Aim: The aim of this systematic review is to assess the factors influencing cervical
cancer screening (CCS) practice among FHWs in Nigeria.
Methods: We conducted a systematic literature search across six (6) electronic data-
bases namely MEDLINE, Embase, Scopus, African Index Medicus, CINAHL, and Web
of Science between May 2020 and October 2020. Reference list and grey literature
search were conducted to complement database search. Four reviewers screened
3171 citations against the inclusion criteria and critically appraised the quality of eligi-
ble studies. Narrative synthesis was used in summarising data from included studies.
Results: Overall, 15 studies met the inclusion criteria and were all quantitative cross-
sectional studies. Included studies sampled a total of 3392 FHWs in Nigeria. FHWs
had a high level of knowledge and positive attitude towards CCS. However, CCS
uptake was poor. Predominant barriers to CCS uptake were the cost of screening,
fear of positive results, lack of test awareness, reluctance to screen, low-risk percep-
tion, and lack of time. In contrast, being married, increasing age, awareness of screen-
ing methods, and physician recommendation were the most documented facilitators.
Conclusion: This study revealed that a complex interplay of socioeconomic, struc-
tural, and individual factors influences CCS among FHWs in Nigeria. Therefore,
implementing holistic interventions targeting both health system factors such as cost
of screening and infrastructure and individual factors such as low-risk perception and
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fear of positive result affecting FHWs in Nigeria is critical to reducing the burden of
cervical cancer.
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1 | INTRODUCTION
Cervical cancer represents a significant threat to reducing global
health inequalities and achieving sustainable development goals. This
disease is the commonest gynaecological cancer affecting women
especially in low and middle-income countries (LMICs).1 Despite being
largely preventable, an estimated 570 000 cervical cancer cases and
311 000 deaths from the disease occurred in 2018.2 It is frightening
to note that over 85% of cervical cancer incidence and mortality occur
in LMICs including Nigeria where organised population cervical cancer
screening (CCS) programmes are inadequate and treatment options
limited.3,4 In contrast, high-income countries have witnessed almost
70% decrease in cervical cancer burden over the last 50 years upon
the introduction of organised CCS programmes.5 Such disparities
between countries demonstrate stark inequalities in healthcare
resources and enduring socioeconomic barriers especially in LMICs.6,7
In Nigeria, cervical cancer is the second principal cause of cancer
morbidity and mortality with an estimated incidence of 14 943 cases
and 10 403 deaths in 2018.2 In the absence of improvements to cur-
rent cervical cancer prevention strategies in Nigeria, an estimated
51 million women aged 15 and above will be at risk of developing cer-
vical cancer.8 The enormity of the impact of cervical cancer observed
in terms of man-hour loss and medical costs results in about $3.3 mil-
lion/disability adjusted life years lost annually.9 The burden placed on
women by this disease contributes to the perpetuation of poverty and
disruption of the socio-economic fabric of both families and
communities.7,9
Fortunately, we are witnessing a shift from the fatalistic accep-
tance of cervical cancer to cautious optimism for its elimination due
to growing knowledge of the natural history of disease and advance-
ments in prevention.10,11 The natural history of cervical cancer allows
for multiple interventions – primary, secondary, and tertiary.12 First,
the well-established evidence that persistent infection with high-risk
Human Papillomavirus (HPV) subtypes is the principal causal factor in
99.7% of all cervical cancer cases13 stimulated vaccine develop-
ment.14 Despite promising results from HPV vaccination, glaring
inequalities in vaccine access and failure of vaccines to protect against
all cancer-inducing HPV strains makes screening the best-buy in the
continuum of interventions against cervical cancer.15–17 Three major
CCS methods are the Papanicolaou smear test, HPV-based testing,
and visual inspection with acetic acid (VIA).18–20
Regrettably, LMICs including Nigeria are lagging in the imple-
mentation of organised CCS using any of the methods due to vari-
ous challenges; absence of national CCS policies and guideline,
paucity of resources, weak political commitment, and deficient
health systems.21–24 Consequently, available CCS services in
Nigeria are mostly opportunistic, inequitably distributed, and
reach a small proportion of eligible women.25 It becomes worri-
some knowing that only 8.7% of all eligible women have been
reached with opportunistic screening in Nigeria.26 Such poor
screening rate has been linked to a spectrum of factors; weak
health system, poor awareness, low-risk perception, sociocultural
barriers, fear of positive result, poverty, and acceptability of avail-
able screening options.27–30 Despite the emphasis on taking
advantage of women's contact with the health system to provide
CCS services, evidence indicates that such opportunities have
been missed.28,31
Given the poor screening status of women in Nigeria, calls for
addressing these missed opportunities for CCS have been made.1,25,31
At the core of efforts to improve screening uptake lie female health
workers (FHWs). Evidence demonstrates that health personnel rec-
ommendation is a key driver of CCS uptake especially in situations
where motivation may be inadequate.32,33 For instance, Okunowo
and Smith-Okonu33 found that 53% of women who received CCS in a
secondary facility in Lagos reported recommendation by doctor/nurse
as a key motivating factor. Undoubtedly, FHWs as role models in
healthcare are expected to facilitate a supportive environment that
encourages women to utilise screening opportunities.34 Equally
important is that the profession of FHWs does not preclude them
from the risk associated with cervical cancer.
Therefore, understanding determinants such as cervical cancer-
related knowledge, attitudes, and screening practices among FHWs
could improve overall screening uptake by informing policy initiatives
and intervention design.35 This study is the first systematic review
aimed at synthesising and generating robust evidence on the factors
influencing CCS uptake among FHWs in Nigeria. Additionally, this sys-
tematic review will highlight CCS related knowledge, attitudes, and
practices which are valuable in improving screening uptake for the
general population.
2 | METHODOLOGY
The method adopted for this study was informed by the guidelines
contained in the Centre for Reviews and Dissemination (CRD)
guidance for undertaking reviews in healthcare36 and The
Cochrane Handbook for Systematic Reviews Version 6.1.37 This
study is reported in accordance with the preferred reporting items
for systematic reviews and meta-analyses (PRISMA) guidelines.38
The protocol (https://www.crd.york.ac.uk/prospero/display_record.
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php?ID=CRD42020186750) for this study is registered with The Inter-
national Prospective Register of Systematic Reviews (PROSPERO).
2.1 | Search strategy and data sources
The systematic search for primary studies relevant to the review
question ‘what are the factors influencing CCS uptake among FHWs
in Nigeria’ included keywords and related terms derived from scop-
ing search and entry terms of Medical Subject Headings (MeSH).
These terms were combined with Boolean operators to ensure bal-
anced sensitivity and precision during database search. These terms
include; Female health* workers OR Health personnel* OR Nurs*
AND Cervical screening OR Early detection of cancer OR Pap*
smear OR HPV testing AND Awareness OR Attitudes OR Practices
OR Determin* OR Access OR Facilitators OR Barriers OR Socioeco-
nomic AND Nigeria* OR Sub Sahara* Africa OR Low and middle-
income countr*. Six (6) electronic databases namely MEDLINE,
Embase, CINAHL, Scopus, African Index Medicus, and Web of Sci-
ence were searched between May to June 2020 and a repeat search
conducted in October 2020. We utilised unique syntax and symbols
(truncations or wildcards) to maintain consistency in search across
selected databases. To ensure the rigour of our search in obtaining
relevant primary studies, we identified key papers that met set inclu-
sion criteria before conducting database search. Upon obtaining the
search results, these key papers were identified showing that our
search was robust.39
Furthermore, we carried out a supplementary search for grey
literature and studies not indexed in selected databases using
Google and Google Scholar. The first 15 pages of results were
retained and examined for relevant primary studies. Reference list
search of all included studies was conducted to identify related
articles. No time or language restrictions were applied in the
course of systematic search to allow for rigour. Detailed search
strategy and outcomes from selected databases are attached as
appendices (Tables A1–A4).
2.2 | Eligibility criteria
The inclusion and exclusion criteria for this systematic review were
informed by the PIOS-based review question. The eligibility criteria
for this study are delineated in Table 1. Included studies in this sys-
tematic review met all the inclusion criteria and none of the exclusion
criteria. Specifically, this systematic review focused on quantitative
studies reporting outcomes of interest such as knowledge, attitude,
practices, and factors influencing CCS among FHWs in Nigeria.
2.3 | Study selection
All studies obtained from database and grey literature search were saved
in Zotero Library version 5.0.84 for storage, duplicate removal, and study
selection based on predetermined eligibility criteria. A total of 3171 cita-
tions were retrieved from the systematic search. After duplicate removal,
we utilised the two-stage recommendation of the CRD in study selection:
(a) Initial screening of titles and abstracts against the eligibility criteria to
identify relevant papers and (b) Screening of full-text papers identified as
potentially relevant from the first stage.36 Four independent reviewers
(O.E., A.S., A.D., N.B.) were employed across these stages (two for each
stage) to allow for reliability and avoid reviewer fatigue.40 Studies that did
not meet the inclusion criteria were excluded and reasons for such exclu-
sion stated (Appendix 2). Efforts were made to obtain relevant papers in
this study through the Teesside University Library and contacting authors;
three papers were not available after these efforts. Discrepancies
between reviewers was discussed and resolved through a consensus.41
The PRISMA four-phase flow diagram was used in reporting study selec-
tion processes (Figure 1).
2.4 | Study quality appraisal
The quality of all the primary studies included in this systematic
review was critically appraised independently by two reviewers
TABLE 1 Eligibility criteria for the systematic review
S/n Parameters Inclusion criteria Exclusion criteria
1 Study population (P) Studies focusing on FHWs irrespective of cadre Studies focusing on general women population or non-
FHWs
2 Intervention (I) Studies focusing on CCS Studies focusing on primary prevention (vaccination) or
tertiary prevention approaches to cervical cancer
3 Study focus (O) Studies reporting factors influencing CCS uptake Studies not reporting barriers or facilitators of CCS
uptake
4 Study location (S) Studies conducted in Nigeria Studies conducted outside of Nigeria
5 Study design Observational studies with either quantitative or
mixed-method study design with distinctive
quantitative reporting of the outcomes of interest
Observational studies with qualitative design or mixed-
method study design without distinctive quantitative
reporting of the outcomes of interest
6 Access to full text Studies that are accessible and available in full text Studies with insufficient information on methodology
and outcomes of interest due to full-text restriction.
Abbreviations: CCS, cervical cancer screening; FHWs, female health workers.
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(O.E. and B.D.) using the AXIS tool checklist for Cross-sectional
studies (Appendix 3).42 Any disagreement in quality assessment
was resolved through discussion. Specifically, the AXIS tool for
cross-sectional studies is a 20-point questionnaire directed at the
quality of study design, reporting, and risk of bias.42 The key focus
of the AXIS tool include (a) study design; (b) sample size
justification; (c) target population; (d) sampling frame; (e) sample
selection; (f ) measurement validity and reliability; (g) overall
methods. Quality appraisal outcomes for included studies were
categorised as low, moderate, and high quality. These categories
were informed by the level of description of study design and clar-
ity in reporting study components including the risk of bias.
F IGURE 1 Preferred reporting items for systematic reviews and meta-analyses flow diagram showing the study selection process
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2.5 | Data extraction
Data from included studies was extracted using a predetermined Micro-
soft Excel data extraction table adapted from the Cochrane Data collec-
tion form to suit the objectives of our review (Appendix 4). Data
extracted from studies included: (a) bibliographic information; (b) study
objective; (c) study design (methodology and sample size); (d) participant
characteristics (socio-demographic variables); (e) results or key findings; (f)
conclusion including the recommendation for research or practice.43 Data
extraction was carried out by one reviewer (O.E.) and subsequently
assessed by a second reviewer (A.S.) to ensure quality. Any observed dis-
crepancies were addressed through discussion.
2.6 | Data analysis and synthesis
A critical evaluation of included studies revealed their unsuitability for
meta-analysis due to statistical heterogeneity arising from variation in
measurements.36,37 Consequently, a narrative synthesis of quantita-
tive data was adopted in synthesising results from included studies.44
In applying the narrative synthesis approach, the study characteristics
and findings from included studies were summarised and contextually
described to answer the review question. The results are presented as
textual narratives in combination with tables highlighting relevant out-
comes. The primary outcome measurements to be analysed in this
systematic review are (a) Knowledge of CCS: This refers to an under-
standing of the benefits of CCS. (b) Attitude towards screening: This
includes the willingness to engage in screening or intention to recom-
mend screening to other women. (c) CCS practices: This refers to the
utilisation of CCS services. (d) Barriers to CCS: This refers to reasons
for not utilising screening services e. Facilitators of CCS: This refers to
factors enabling the use of screening services.
3 | RESULT
A systematic search of six electronic databases (n = 2947) and grey
literature sources such as Google and Google scholar (n = 224)
yielded a total of 3171 citations (Figure 1). At the end of duplicate
removal using Zotero, 2957 unique citations were included for
screening via titles and abstract. After initial title and abstract screen-
ing to identify potentially relevant papers that answer the review
question and fits the inclusion criteria, 2919 citations that did not fit
the inclusion criteria or answer the review question were removed
and 38 citations were retained for full-text screening to determine
their eligibility for final inclusion. Upon the application of inclusion
criteria and full-text review by two independent reviewers (O.E. and
A.S.), 13 studies were included for the review. Furthermore, reference
list search identified an additional two papers bringing the total num-
ber of included studies to 15.45–59 Reasons for exclusion of papers
were: different study location (n = 7), different study population
(n = 5), multiple publication (n = 2), focus on other interventions
(n = 7), full text unavailable (n = 3), and review (n = 1).
3.1 | Study characteristics
Summary characteristics of all included primary studies are displayed
in Table 2. All included studies (n = 15) were quantitative cross-sec-
tional studies. Similarly, questionnaires were the key data collection
for all included studies. The 15 studies included in this systematic
review sampled a total of 3392 FHWs; study sample sizes ranged
from 40 to 503.56,52 In determining study sample sizes, only 10 studies
documented the justification for selecting a particular sample
size.46,48,49,50,52,53,54,55,57,58 Majority of the studies (n = 8) included
different cadres of FHWs,45,46,48,53,54,56,57,58 two studies involved
only medical doctors,49,55 and five focused solely on
nurses.47,50,51,52,59 The age of participants in selected studies was
measured in a range between 20 and 60 years.
Included primary studies were published between 2003 and
2019; with the highest number of the studies (n = 4) being published
in 2019. While time limit was not applied, systematic search for rele-
vant studies was delimited to Nigeria. Analysis of study location for
included studies demonstrated country-wide coverage as each of the
six geopolitical zones had at least one study; North Central (n = 2;
Abuja and Ilorin), North East (n = 1; Maiduguri), Northwest (n = 1;
Sokoto), South East (n = 4; Awka, Enugu, and two studies in
Abakaliki), South-South (n = 3; Benin, Uyo, and Rivers), and South-
West (n = 4; Lagos, Ogun, and two studies in Ibadan). Majority of
included studies were conducted in tertiary health institutions
(n = 10), three were multi-centred studies involving a mix of tertiary
and secondary health facilities, and two focused on professional asso-
ciations (Medical Women Association).
3.2 | Quality assessment
Majority of included studies (n = 10) were moderate in terms of study
quality, two were categorised as having low quality, and three studies
were regarded as having high quality (Table 2). Predominant methodo-
logical factors responsible for weakness in appraised studies include
non-justification of sample size, poor documentation of the reliability
and validity of data collection tools, and non-disclosure of risk of bias
in study outcomes. For instance, the justification of study sample size
is recognised as good practice and is crucial in identifying the exis-
tence and magnitude of an effect.60
Furthermore, only two studies53,54 out of the 15 included dis-
cussed the limitations of their study. About half of the studies (n = 7)
disclosed either funding sources or conflict of interest that may influ-
ence author interpretation of findings.
3.3 | Awareness and knowledge of CCS
among FHWs
Knowledge and/or awareness of CCS was a key outcome measure-
ment across selected studies. Awareness of CCS focused on general
information about its existence; have FHWs heard of CCS? While
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TABLE 2 Description of included studies
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Knowledge, Attitude and Practice of Cervical Smear as a







3 Udigwe (2006) Knowledge, attitude, and practice of cervical cancer screening





An appraisal of the level of awareness and utilisation of the
Pap smear as a cervical cancer screening test among female








5 Dim et al. (2009) Improved awareness of Pap smear may not affect its use in
Nigeria: a case study of female medical practitioners in
Enugu, South-Eastern Nigeria (Enugu)
80 Doctors Moderate
6 Awodele et al.
(2011)
A Study on Cervical Cancer Screening Among Nurses in Lagos
University Teaching Hospital, Lagos, Nigeria (Lagos)
200 Nurses Moderate
7 Unang et al.
(2011)
Awareness and Practice of Cervical Smear as A Screening
Procedure for Cervical Cancer among Female Nurses in A




Perception and utilisation of cervical cancer screening services
among female nurses in University College Hospital, Ibadan,
Nigeria (Ibadan)
503 Nurses Moderate
9 Oche et al. (2013) Cancer of the cervix and cervical cancer screening: Current
knowledge, attitude, and practices of female health workers






10 Takai et al. (2015) Awareness and utilisation of Papanicolaou smear among







11 Jagun et al. (2016) Uptake of Cervical Cancer Screening Services Among Female
Medical Practitioners in Ogun State, South-West Nigeria
(Ogun)
85 Doctors Moderate
12 Daniyan et al.
(2019)
Assessment of Knowledge, Attitudes and Practice of Cervical
Cancer Screening Among Female Health Workers in a
Tertiary Health Facility in South-East Nigeria (Abakiliki)
40 FHWs Low
13 Omonua et al.
(2019)
A Study on the Awareness and Utilisation of Pap Smear





14 Awoyesuku et al.
(2019)
Knowledge, Uptake and Barriers to Pap Smear Test among








15 Ifemelumma et al.
(2019)
Cervical Cancer Screening: Assessment of Perception and
Utilisation of Services among Health Workers in Low
Resource Setting (Abakaliki)
408 Nurses High
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knowledge of CCS focused on assessment of specific information
about the benefits of CCS among FHWs. Five studies reported only
awareness of CCS,47,48,49,54,55 seven studies reported both awareness
and knowledge of CCS,50,51,52,53,57,58,59 and three studies reported
only knowledge.45,46,56 Eight studies reported knowledge outcomes
as proportions (n = 8) while two studies45,56 measured knowledge
using a Likert scale. An understanding of the use and benefits of CCS
was a measurement criterion for screening knowledge.
Overall, awareness and knowledge of CCS use were high across
selected studies (Table 3). Awareness among FHWs ranged from 6155
to 100%.49,59 Similarly, knowledge levels ranged from 54.552 to
90.5%.53 For studies that used a Likert scale, mean knowledge scores
ranged from 3.32 to 6.47 out of 8 in Ayinde and Omigbodun45 and
from 4.55 to 4.68 out of five in Daniyan et al.56 Beyond the knowl-
edge of the use screening, selected studies assessed other areas of
screening knowledge. Particularly, knowledge of screening interval,
target population, screening results, and screening methods was
investigated.
FHWs knowledge on recommended CCS interval and target popula-
tion eligible for screening was found to be poor.46,50,57,59 Similarly, an
understanding of screening results among FHWs was found to be inade-
quate.50,57 For studies that assessed knowledge of screening methods,
pap smears were reported as the most popular screening method. Among
studies that stratified CCS knowledge by cadre of FHWs, knowledge was
observed to be ‘profession-dependent’ as doctors and nurses were more
knowledgeable compared to others.45,48
Furthermore, 60% of the studies (n = 9) reported sources of CCS
information for FHWs. Prevalent sources of information reported by
FHWs across selected studies include media, school lectures/medical
training, health professionals/colleagues, seminar, and friends.
TABLE 3 Summary of CCS outcome measurements
S/n Author, year Knowledge/awareness of CCS Attitudes towards CCS CCS practices
1 Ayinde and Omigbodun,
(2003)
Mean knowledge scores:
Doctors = 6.47/8, Nurses = 4.72/8,
Hospital maids = 3.32/8
Willingness to test = Yes
(53.9%)
Ever had a pap smear = Yes (6.8%)
2 Aboyeji et al. (2004) Knowledge = Yes (69.8%) Willingness to test = Yes
(19.6%)
Ever had a pap smear = Yes (3%)
3 Udigwe, (2006) Awareness = Yes (87.1%) NA Ever had a pap smear = Yes (5.7%)
4 Gharoro and Ikeanyi, (2006) Awareness = Yes (64.7%) Willingness to test = Yes
(64.7%)
Ever had a pap smear = Yes (14.1%)
5 Dim et al. (2009) Awareness = Yes 100% NA Ever had a pap smear = Yes (18%)
6 Awodele et al. (2011) Awareness = Yes (91%)
Knowledge = Yes (60%)
Perception of screening




Ever had a pap smear = Yes (21.5%)
7 Unang et al. (2011) Awareness = Yes (94.3%)
Knowledge = Yes (79.5%)
NA Ever had a pap smear = Yes (7.4%)
8 Arulogun and Maxwell
(2012)
Awareness = Yes (80.9%)
Knowledge = Yes (54.5%)
Willingness to test = Yes
(81%)
Ever had a pap smear = Yes (34.5%)
9 Oche et al. (2013) Awareness = Yes (98.6%)
Knowledge = Yes (90.5%)
Willingness to test = Yes
(77.7%)
Intention to recommend
screening = Yes (81.9%)
Ever had a pap smear = Yes (10%)
10 Takai et al. (2015) Awareness = Yes (94%) Willingness to test = Yes
(70.6%)
Ever had a pap smear = Yes (23.3%)
11 Jagun et al. (2016) Awareness = Yes (61%) NA Ever had a pap smear = Yes (39.8%)
12 Daniyan et al. (2019) Mean knowledge scores 4.55–4.68/5. Perception of screening
importance = 4.39–
4.81/5.
Ever had a pap smear = Yes (54.1%)
13 Omonua et al. (2019) Awareness = Yes (97.5%)
Knowledge = Yes (58%)
NA Ever had a pap smear = Yes (23.5%)
14 Awoyesuku et al. (2019) Awareness = Yes (89.4%)
Knowledge = Yes (78.5%)
NA Ever had a pap smear = Yes (16.9%)
15 Ifemelumma et al. (2019) Awareness = 100%,




Ever had a pap smear = Yes (20.6%)
Abbreviations: CCS, cervical cancer screening; NA, not assessed.
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3.4 | Attitude of FHWs towards CCS
Out of the 15 included studies for this systematic review, 60% (n = 9)
assessed the attitude of FHWs towards CCS (Table 3). Core informa-
tion elicited by studies investigating attitude of FHWs towards CCS
includes the willingness to test (n = 6),45,46,48,52,53,54 perception of
screening importance (n = 2),50,56 and intention to recommend/
routine recommendation of CCS (n = 3).50,53,59 Overall, the majority
of the studies reported positive attitude towards CCS among FHWs.
In terms of FHWs willingness to screen, the majority (n = 5) of
the studies reported high willingness to have a CCS test ranging from
53.9% in Ayinde and Omigbodun45 to 81% in Arulogun and Max-
well.52 Conversely, Aboyeji et al46 documented negative attitude
among FHWs as 77.4% were unwilling to participate in screening due
TABLE 4 Barriers to CCS uptake
S/n Reported barriers No. of studies Author(s)
1 Cost of screening n = 9 Ayinde and Omigbodun (2003), Aboyeji et al. (2004);
Udigwe (2006); Awodele et al. (2011); Unang et al.
(2011); Arulogun and Maxwell (2012); Takai et al.
(2015); Jagun et al. (2016); Awoyesuku et al. (2019)
2 Fear of positive result n = 9 Aboyeji et al. (2004), Udigwe (2006), Dim et al. (2009),
Unang et al. (2011), Arulogun and Maxwell (2012),
Oche et al. (2013), Jagun et al. (2016), Ifemelumma
et al. (2019), Awoyesuku et al. (2019),
3 Lack of test awareness/ignorance n = 8 Ayinde and Omigbodun (2003); Gharoro and Ikeanyi
(2006), Udigwe (2006), Jagun et al. (2016), Awodele
et al. (2011), Arulogun and Maxwell, (2012), Oche
et al. (2013), Ifemelumma et al. (2019)
4 Low risk perception n = 8 Ayinde and Omigbodun (2003), Aboyeji et al. (2004),
Gharoro and Ikeanyi (2006), Udigwe (2006), Unang
et al. (2011), Oche et al. (2013), Omonua et al.
(2019).
5 Reluctance/no reason n = 7 Ayinde and Omigbodun (2003), Aboyeji et al. (2004),
Udigwe (2006), Dim et al. (2009), Awodele et al.
(2011), Unang et al. (2011), Omonua et al. (2019)
6 Lack of time/being busy n = 6 Dim et al. (2009), Awodele et al. (2011), Arulogun and
Maxwell, 2012; Ifemelumma et al. (2019), Omonua
et al. (2019), Awoyesuku et al. (2019).
7 Poor knowledge of testing facilities n = 5 Awodele et al. (2011), Unang et al. (2011), Arulogun
and Maxwell (2012), Takai et al. (2015), Ifemelumma
et al. (2019).
8 Neglect of screening n = 5 Awodele et al. (2011), Unang et al. (2011), Ifemelumma
et al. (2019) Omonua et al. (2019), Awoyesuku et al.
(2019)
9 Sexually inactive n = 4 Ayinde and Omigbodun, 2003; Arulogun and Maxwell,
2012; Ifemelumma et al. (2019), Awoyesuku et al.
(2019).
10 Lack of screening services n = 3 Gharoro and Ikeanyi (2006), Jagun et al. (2016),
Awoyesuku et al. (2019).
11 Religious/cultural beliefs n = 2 Aboyeji et al. (2004), Gharoro and Ikeanyi (2006).
12 Laziness n = 2 Dim et al. (2009), Jagun et al. (2016).
13 Cumbersome procedure n = 2 Arulogun and Maxwell (2012), Ifemelumma et al.
(2019)
14 Lack of money n = 1 Awodele et al. (2011)
15 Husband disapproval n = 1 Aboyeji et al. (2004)
16 Preservation of virginity n = 1 Dim et al. (2009)
17 Being young n = 1 Unang et al. (2011)
18 Lack of recommendation n = 1 Takai et al. (2015)
19 Gender of screening provider n = 1 Oche et al. (2013).
20 Fear of pain n = 1 Oche et al. (2013)
Abbreviation: CCS, cervical cancer screening.
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to low-risk perception. Overall, perception towards the importance of
CCS was good as 89% of FHWs in Awodele et al50 opined that it is
advisable to screen. Similarly, Daniyan et al56 reported an attitude
range of 4.39–4.81 on a scale of five indicating that the majority of
sampled FHWs perceived CCS as beneficial.
Furthermore, a wide gap was observed between the intention to
recommend CCS and actual recommendation practices among FHWs.
While reported intention to recommend screening to others was as
high as 81.9%,53 low practice of routine screening recommendation
ranging from 34 to 43.3% was documented.50,59
3.5 | CCS practices among FHWs
All 15 studies for this systematic review assessed CCS practices among
FHWs (Table 3). The previous history of CCS uptake among FHWs was a
key practice indicator across selected studies. Overall, a trend of poor
utilisation of CCS was observed among FHWs. The proportion of FHWs
that have previously screened ranged from 3% in Aboyeji et al46 to
54.1% in Daniyan et al.56 In contrast, the proportion of FHWs without
any history of CCS was high, ranging from 45.9 to 97%.
Again, among studies that stratified screening practices by cadre
of FHWs, a significant association was observed between CCS uptake
and the cadre of FHWs.46,48 In Aboyeji et al,46 screening uptake was
significantly different between doctors (6.5%) and other FHWs such
as medical laboratory scientists (4.3%) and nurses (1.7%). Gharoro and
Ikeanyi48 documented higher screening rates (73.1%) among nurses
compared to hospital maids (0%) who had little or no medical training.
3.6 | CCS related barriers and facilitators
Fourteen studies documented barriers to CCS uptake among FHWs.
A total of 20 barriers were identified as key reasons for non-utilisation
of cervical cancer services among FHWs in Nigeria (Table 4). These
barriers could be broadly categorised into health system and
individual-level barriers. Individual-level barriers refer to those factors
impeding the uptake of CCS at the level of the individual FHW. Preva-
lent individual-level barriers reported across primary studies include
fear of positive result, low-risk perception, lack of test awareness/
ignorance, and lack of time/being busy.
In contrast, barriers at the health system level refer to health sys-
tem or service delivery factors that result in the exclusion of FHWs
who may want to screen. Core institutional barriers reported across
selected studies include the cost of screening, cumbersome nature of
the procedure, lack of CCS recommendation, and gender of screening
provider.
Furthermore, 53% of included studies (n = 8) reported facilitators
of CCS among FHWs. Ten facilitators were identified (Table 5) as rea-
sons for screening among FHWs who had previously screened. Major
reasons for screening include being married, increasing age of the
FHW, physician recommendation, and being ill.
4 | DISCUSSION
This systematic review investigated factors influencing CCS uptake
among FHWs in Nigeria. This study observed a high level of aware-
ness and knowledge of the use of cervical screening among FHWs.
While good knowledge of CCS use is fundamental to cervical cancer
prevention, it is not surprising that a significant proportion of FHWs
understood the need for screening.50,53 By their profession, health
workers are trained to respond to varying health challenges and are
expected to be knowledgeable about cervical cancer-related issues.56
Similarly, pap smear was the most popular screening method among
FHWs.52,59 For instance, Ifemelumma et al59 reported that 89.2% of
FHWs knew pap smear compared to 41.2 and 25.5% with knowledge
of VIA and HPV-based testing, respectively. The popularity of pap
TABLE 5 Facilitators of CCS uptake
S/n Facilitators No. of studies Author(s)
1 Being married/marital status n = 4 Aboyeji et al. (2004), Oche et al. (2013), Ifemelumma
et al. (2019), Awoyesuku et al. (2019).
2 Increasing age n = 4 Dim et al. (2009), Awodele et al. (2011), Oche et al.
(2013), Ifemelumma et al. (2019).
3 Awareness of screening methods n = 3 Udigwe, (2006), Awodele et al. (2011), Jagun et al.
(2016).
4 Being Ill n = 2 Dim et al. (2009), Jagun et al. (2016)
5 Physician recommendation n = 2 Oche et al. (2013), Jagun et al. (2016)
6 Membership of clinical department n = 1 Aboyeji et al. (2004)
7 Cadre of FHWs n = 1 Arulogun and Maxwell (2012)
8 Higher educational attainment n = 1 Takai et al. (2015)
9 Availability of screening services n = 1 Jagun et al. (2016)
10 Parity n = 1 Ifemelumma et al. (2019)
Abbreviation: CCS, cervical cancer screening.
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smear over other methods may emanate from its longstanding use as
the traditional screening method and/or gaps in the promotion of
other screening methods.
While the benefits of screening were well understood by FHWs,
this study revealed inadequate knowledge of screening interval, rec-
ommended target population, and interpretation of screening results
among FHWs.46,50,57,59 Such inadequacy in comprehensive screening
knowledge highlights existing knowledge and competency gaps and
raises concern on several factors influencing cervical cancer informa-
tion available to FHWs; source, thoroughness, and coherency of infor-
mation. Media, medical literature, health professionals, and school
represented the major sources of cervical screening information for
FHWs. Medical literature and school as an information source suggest
the provision of fundamental cervical cancer education during the
medical training of FHWs.46,58 Similarly, FHWs reporting health pro-
fessionals or colleagues as a source of information demonstrates that
workplace interactions with fellow professionals contribute to the
acquisition of cervical cancer knowledge.51 In contrast, the prevalence
of media as a major information source across a substantial number of
studies raises concern. This is because the information from media
may lack rigour in its production, be unreliable to inform health knowl-
edge, and may misrepresent current evidence on health issues.61
Again, despite the relevance of continuing medical education (CME)
to meeting contemporary skills and information needs of health per-
sonnel, only a minute number of studies reported CME as an informa-
tion source.57,59 Such observation suggests possible low prioritisation
of cervical cancer in the CME curriculum for health workers.
This study revealed that FHWs hold positive attitudes towards
CCS. Research suggests that favourable attitudes towards CCS have a
profound influence on CCS practice among individuals.62 Majority of
the studies documented that a significant proportion of FHWs per-
ceived screening as an important procedure, were willing to partake in
screening, and intend to recommend screening to other eligible
women.53,56 While FHWs favourable attitude towards CCS is not
unexpected due to their background, such attitudes play a significant
role in creating a supportive environment that facilitates screening
uptake among their colleagues and women in the general popula-
tion.34 Furthermore, the observed disparity between willingness to
recommend screening and actual recommendation practices among
FHWs in Nigeria highlights the need to translate behavioural inten-
tions into desired practices among this group.50
Regrettably, this study highlighted poor screening practices
among FHWs despite possessing a high level of knowledge and good
attitude towards CCS. This observation raises serious concerns as
FHWs are expected to be champions of positive health behaviour and
practices aimed at protecting and improving health.53 Even more per-
turbing was the observation of poor screening uptake among FHWs
in facilities where services are readily available.56 Observed low
uptake of CCS among a group perceived to be at the frontline of
health protection portends abysmal outcomes for women in the gen-
eral population who may lack appropriate knowledge. Additionally,
such poor practice of CCS demonstrates that utilisation of screening
is not entirely dependent on knowledge and attitudes but also
influenced by broader factors.49 Moreover, it has been suggested that
alongside knowledge and attitude, a complex interplay of socioeco-
nomic and cultural factors that mediate consumption of health ser-
vices could predict CCS uptake.48
A mix of health system and individual level barriers were identi-
fied as major reasons for not screening among FHWs. The preponder-
ance of screening cost as a key barrier represented a key structural
challenge impeding CCS uptake among FHWs. This finding agrees
with previous evidence highlighting the significant impact of socioeco-
nomic status on the uptake of screening.63,64 The cost of CCS which
ranges from $25 to 30 (₦10 250–₦12 300) could be prohibitive as
payment for the service is mostly reliant on out-of-pocket spend-
ing.30,65 Considering that the cost of CCS could be up to 41% of the
monthly minimum wage (₦30 000), inability to afford screening by
FHWs may result from poor remuneration, competing needs, and/or
poor coverage of existing health insurance schemes.50 Financial con-
straints may also reflect wider economic issues in a country where
more than 50% of the population lives below $2 daily.66 Other institu-
tional challenges such as cumbersome nature of the procedure and
lack of CCS recommendation highlight the need for revaluation of cur-
rent practices to facilitate an environment that encourages screening
uptake.
Predominant screening barriers at the individual level such as fear
of positive result, low-risk perception, lack of test awareness, and
reluctance to screen are worrisome to be observed among FHWs.
These findings are consistent with the results of systematic reviews
conducted by Lim and Ojo24 and Black et al.64 Fear of positive result
may emanate from either fatalistic beliefs that positive CCS
result equals a death sentence or potential labelling due to perceived
association of cervical cancer with promiscuity.24,67 Equally con-
cerning is observed low cervical cancer risk perception among FHWs
who felt they were not susceptible to the disease. Such poor percep-
tion of the threat posed by cervical cancer may precipitate ignorance
or reluctance to utilise CCS services as elicited in the majority of the
reviewed studies. Consequently, cervical cancer may be detected
among this group at advanced stages due to poor screening prac-
tices.54 Hence, it becomes pertinent that interventions must prioritise
risk perception among this group to improve CCS.68
This study identified marital status, increasing age, awareness of
screening methods, and physician recommendation as significant facil-
itators for CCS uptake among FHWs. These facilitators align with
those documented in a similar systematic review by Black et al64 in
Uganda. In some selected studies, younger and unmarried FHWs
believe that only older and married women were at greater risk of
developing cervical cancer.46,59 In contrast, evidence suggests that
older people may have better risk perception which subsequently
facilitates the utilisation of preventive services such as screening.52
Again, being married may predispose women to a greater need for
health services which include CCS. Furthermore, identifying physi-
cians' awareness of screening methods and subsequent recommenda-
tion as facilitators of CCS uptake among FHWs highlights the need to
leverage existing opportunities for cervical cancer education and
screening recommendation.
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4.1 | Study limitations and strengths
It is advisable to keep several caveats in mind when interpreting the
findings of this study due to inherent limitations. Although we
searched for grey literature, the non-inclusion of a few eligible primary
studies due to their inaccessibility may weaken the overall conclusion
of the study. Second, all studies included in this review were of quan-
titative cross-sectional study designs. Cross-sectional studies are sus-
ceptible to a spectrum of bias; exposure-effect bias, recall bias, and
response bias.69 Third, heterogeneity in outcome measurements
across studies made comparison and summarisation of results difficult.
Finally, the use of narrative synthesis which is largely dependent on
the researcher interpretation of primary findings may introduce
interpretive bias.
Nonetheless, this study possesses several strengths that improve
the validity of drawn conclusions. First, the use of independent
reviewers in study screening and selection, quality appraisal, and data
extraction. Next, this study relied on a robust and exhaustive search
strategy across selected databases and grey literature sources. Finally,
we adhered to the UK Economic and Social Research Council's
established principles guiding the conduct of narrative synthesis
of data.
5 | CONCLUSION
By identifying and synthesising results from available primary studies,
this review provides robust evidence that can inform policy and pro-
gramme initiatives directed at factors influencing CCS among FHWs
in Nigeria. This study observed that a complex interplay of socioeco-
nomic, structural, and individual factors influences CCS among FHWs
in Nigeria. Equally important is the need to translate observed good
knowledge and attitudes among this population into improved CCS.
Hence, implementing holistic interventions targeting both the health
system factors such as cost of screening and infrastructure, and indi-
vidual factors such as low-risk perception and fear of positive result
affecting FHWs in Nigeria is critical to improving CCS outcomes. Con-
sequently, improved screening practices among this group is likely to
trigger a ripple effect of increased CCS utilisation among women who
they come in contact with.
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APPENDIX
TABLE A1 Sample search outcomes (Medline and CINAHL)
Search (S) Search term/keywords PIOS Medline results CINAHL results
S1 (MH “Allied Health Personnel+/OG”) Population 2447 2829
S2 (MH “Health Personnel+”) Population 510 397 579 215
S3 nurse* Population 365 945 518 199
S4 female N5 (health OR healthcare OR health care) N5 (workers
OR personnel OR professionals OR providers OR staff)
Population 1567 842
S5 (MH “Nurses+”) Population 87 267 230 681
S6 S1 OR S2 OR S3 OR S4 OR S5 Population 738 739 875 909
S7 (MH “Uterine Cervical Neoplasms/DI/PC”) Intervention 22 427
S8 cervical screening Intervention 12 685 5492
S9 pap* N5 (smear OR test*) Intervention 28 311 6869
S10 “visual inspection” N5 (“acetic acid” OR “lugol* iodine”) Intervention 629 210
S11 (MH “Colposcopy”) Intervention 6274 1710
S12 Colposcopy Intervention 9194 2345
S13 (MH “Early Detection of Cancer”) Intervention 25 385 9121
S14 hpv testing Intervention 3794 1150
S15 (vaginal OR cervical) N5 smear Intervention 24 768 6861
S16 (vaginal OR pelvic) N5 exam* Intervention 8754 2352
S17 cervical cytology Intervention 5021 1105
S18 cytological screening Intervention 757 77
S19 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR
S15 OR S16 OR S17 OR S18
Intervention 94 572 24 900
S20 (MH “Health Knowledge Attitudes, Practice”) Outcome 178 782
S21 (MH “Health Knowledge Attitudes, Practice”) Outcome 178 782 1925
S22 (MH “Attitude of Health Personnel+”) Outcome 156 791 99 956
S23 (MH “Attitude to Health+”) Outcome 414 103 158 294
S24 knowledge Outcome 772 722 239 323
S25 (MH “Awareness”) Outcome 20 009
S26 Awareness Outcome 157 048 72 065
S27 (MH “Perception+”) Outcome 425 290 83 434
S28 Perception Outcome 434 662 157 496
S29 attitudes Outcome 420 370 334 654
S30 practices Outcome 1 178 333 675 950
S31 enablers Outcome 3245 2139
S32 determin* Outcome 3 556 339 545 669
S33 predictors Outcome 379 894 134 611
S34 difficult* Outcome 629 147 152 346
S35 cost Outcome 642 803 225 728
S36 (MH “Patient Acceptance of Health Care+”) Outcome 150 887
S37 (MH “Socioeconomic Factors+”) Outcome 445 716 352 407
S38 access Outcome 328 113 144 781
S39 socioeconomic Outcome 216 875 107 592
S40 facilitators Outcome 20 745 13 483
S41 promot* Outcome 1 111 525 228 627
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TABLE A1 (Continued)
Search (S) Search term/keywords PIOS Medline results CINAHL results
S42 uptake Outcome 383 350 41 290
S43 challenges Outcome 607 113 179 225
S44 obstacles Outcome 48 460 12 364
S45 S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34
OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41
OR S42 OR S43 OR S44
Outcome 8 849 829 2 500 007
S46 Nigeria* Setting 54 256 9287
S47 subsahara* africa Setting 153 17
S48 sub sahara* africa Setting 22 315 6472
S49 developing countr* Setting 127 986 29 127
S50 low and middle income countr* Setting 18 474 8728
S51 low resource setting* Setting 4604 1821
S52 S46 OR S47 OR S48 OR S49 OR S50 OR S51 Setting 209 756 50 443
S53 (S6 AND S19 AND S45 AND S52) PIOS 143 65
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TABLE A2 Sample search outcome (Embase)
# Query Results
1 exp paramedical personnel/ 525 389
2 exp health care personnel/ 1 672 947
3 nurse*.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
436 419
4 (female adj5 (health or healthcare or health care) adj5 (workers or personnel or professionals or providers or
staff)).mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
41 319
5 exp nurse/ 191 249
6 or/1–5 1 858 408
7 exp uterine cervix tumor/di, pc [Diagnosis, Prevention] 28 540
8 cervical screening.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
4281
9 (pap* adj5 [smear or test*]).mp. [mp = title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term
word]
40 172
10 (“visual inspection” adj5 [“acetic acid” or “lugol* iodine”]).mp. [mp = title, abstract, heading word, drug trade
name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating
subheading word, candidate term word]
1036
11 colposcopy/ 12 538
12 Colposcopy.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
14 347
13 early cancer diagnosis/ 8481
14 hpv testing.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
4219
15 ([vaginal or cervical] adj5 smear).mp. [mp = title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term
word]
4586
16 ([vaginal or pelvic] adj5 exam*).mp. [mp = title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term
word]
15 804
17 cervical cytology.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
5170
18 cytological screening.mp. [mp = title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term
word]
684
19 or/7–18 95 388
20 attitude to health/ 117 813
21 exp health personnel attitude/ 190 498
22 knowledge.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
987 762
23 awareness/ 101 500
24 awareness.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
261 073
25 exp perception/ 377 204
26 Perception.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
377 482
27 attitudes.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
154 176
28 practices.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
297 483
29 enablers.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
3936
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TABLE A2 (Continued)
# Query Results
30 determin*.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
4 951 537
31 predictors.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
388 708
32 difficult*.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
935 275
33 cost.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
944 491
34 exp patient advocacy/or patient attitude/ 92 717
35 exp sociobiology/or socioeconomics/ 161 632
36 access.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
548 036
37 socioeconomic.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
122 627
38 facilitators.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
23 299
39 promot*.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
1 477 929
40 uptake.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
539 149
41 challenges.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
396 902
42 obstacles.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
38 454
43 or/20–42 10 596 239
44 Nigeria*.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading word, candidate term word]
50 728
45 subsahara* africa.mp. [mp = title, abstract, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
295
46 developing countr*.mp. [mp = title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term
word]
142 878
47 (low and middle income countr*).mp. [mp = title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term
word]
27 268
48 low resource setting*.mp. [mp = title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term
word]
6447
49 or/44–48 216 996
50 6 and 19 and 43 and 49 2235
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TABLE A3 Sample search outcome (SCOPUS)
# Search terms Results
14 ((TITLE-ABS-KEY [“Health Personnel” OR nurse*]) OR (TITLE-ABS-KEY ((female) W/5 (health OR healthcare OR “health
care”) W/5 (workers OR personnel OR professionals OR providers OR staff)))) AND ((TITLE-ABS-KEY [“Uterine
Cervical Neoplasms” OR “cancer screening”]) OR (TITLE-ABS-KEY (pap* W/5 [smear OR test*])) OR (TITLE-ABS-KEY
(“visual inspection” W/5 [“acetic acid” OR “lugol* iodine”])) OR (TITLE-ABS-KEY [colposcopy OR “early detection of
cancer” OR “hpv testing”]) OR (TITLE-ABS-KEY ([vaginal OR cervical] W/5 smear)) OR (TITLE-ABS-KEY ([vaginal OR
pelvic] W/5 exam*)) OR (TITLE-ABS-KEY [“cervical cytology” OR “cytological screening”])) AND (TITLE-ABS-KEY
(knowledge OR attitudes OR awareness OR perception OR practices OR enablers OR determin* OR predictors OR
diffcult* OR cost OR “patient acceptance” OR socioeconomic OR access OR facilitators OR promot* OR uptake OR
challenges OR obstacles)) AND (TITLE-ABS-KEY (nigeria* OR “subsahara* africa” OR “sub sahara* africa” OR
“developing countr*” OR “low and middle income countr*” OR “low resource setting”)) View Less
279
13 TITLE-ABS-KEY (nigeria* OR “subsahara* africa” OR “sub sahara* africa” OR “developing countr*” OR “low and middle
income countr*” OR “low resource setting”)
447,121
12 TITLE-ABS-KEY (knowledge OR attitudes OR awareness OR perception OR practices OR enablers OR determin* OR
predictors OR diffcult* OR cost OR “patient acceptance” OR socioeconomic OR access OR facilitators OR promot* OR
uptake OR challenges OR obstacles)
21,457,461
11 (TITLE-ABS-KEY (“Uterine Cervical Neoplasms” OR “cancer screening”)) OR (TITLE-ABS-KEY (pap* W/5 (smear OR
test*))) OR (TITLE-ABS-KEY (“visual inspection” W/5 (“acetic acid” OR “lugol* iodine”))) OR (TITLE-ABS-KEY
(colposcopy OR “early detection of cancer” OR “hpv testing”)) OR (TITLE-ABS-KEY ((vaginal OR cervical) W/5 smear))
OR (TITLE-ABS-KEY ((vaginal OR pelvic) W/5 exam*)) OR (TITLE-ABS-KEY (“cervical cytology” OR “cytological
screening”)) View Less
345,552
10 TITLE-ABS-KEY (“cervical cytology” OR “cytological screening”) 5,060
9 TITLE-ABS-KEY ((vaginal OR pelvic) W/5 exam*) 13,967
8 TITLE-ABS-KEY ((vaginal OR cervical) W/5 smear) 25,292
7 TITLE-ABS-KEY (colposcopy OR “early detection of cancer” OR “hpv testing”) 43,841
6 TITLE-ABS-KEY (“visual inspection” W/5 (“acetic acid” OR “lugol* iodine”)) 800
5 TITLE-ABS-KEY (pap* W/5 (smear OR test*)) 185,789
4 TITLE-ABS-KEY (“Uterine Cervical Neoplasms” OR “cancer screening”) 128,334
3 (TITLE-ABS-KEY (“Health Personnel” OR nurse*)) OR (TITLE-ABS-KEY ((female) W/5 (health OR healthcare OR “health
care”) W/5 (workers OR personnel OR professionals OR providers OR staff)))
614,825
2 TITLE-ABS-KEY ((female) W/5 (health OR healthcare OR “health care”) W/5 (workers OR personnel OR professionals OR
providers OR staff))
2,054
1 TITLE-ABS-KEY (“Health Personnel” OR nurse*) 613,409
TABLE A4 Sample search outcome (Web of Science)
# Search history Results
# 5 #4 AND #3 AND #2 AND #1
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan = All years
99
# 4 TOPIC: (nigeria* OR “subsahara* africa” OR “sub sahara* africa” OR “developing countr*” OR “low and middle
income countr*” OR “low resource setting”)
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan = All years
249,855
# 3 TOPIC: (knowledge OR awareness OR perception OR attitudes OR practices OR enablers OR determin* OR
predictors OR difficult* OR cost OR “patient acceptance” OR socioeconomic OR access OR facilitators OR
promot* OR uptake OR challenges OR obstacles)
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan = All years
15,754,209
# 2 TOPIC: (“uterine cervical neoplasms” OR “cervical screening”) OR TOPIC: (pap* NEAR/5 (smear OR test*)) OR
TOPIC: (“visual inspection” NEAR/5 (“acetic acid” OR “lugol* iodine”)) OR TOPIC: (Colposcopy OR “early
detection of cancer” OR “hpv testing”) OR TOPIC: ((vaginal OR cervical) NEAR/5 smear) OR TOPIC:
((vaginal OR pelvic) NEAR/5 exam*) OR TOPIC: (“cervical cytology” OR “cytological screening”)
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan = All years
131,073
# 1 TOPIC: (“health personnel” OR nurse*) OR TOPIC: (female NEAR/5 (health OR healthcare OR “health care”)
NEAR/5 (workers OR personnel OR professionals OR providers OR staff))
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan = All years
226,839
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TABLE A5 Excluded citations with reasons
S/n Author-date Title Reason
1 Nwobodo and Malami (2005) ‘Knowledge and practice of cervical screening among
female health workers in Sokoto, North Western
Nigeria’
Full text unavailable
2 Addah et al. (2012) ‘Knowledge, attitude and practice of cervical cancer
screening – Papanicolaou test (Pap smear) among
female health care providers in Port Harcourt’
Full text unavailable
3 Kabir et al. (2005) ‘Awareness and Practice of Cervical Cancer Screening
among Female Health Professionals in Murtala
Mohammed Specialist Hospital, Kano’
Full text unavailable
4 Aniebue and Aniebue (2010) ‘Awareness and practice of cervical cancer screening




5 Ndikom and Ofi (2012) ‘Awareness, perception and factors affecting utilisation
of cervical cancer screening services among women
in Ibadan, Nigeria: a qualitative study’
Different study population
excluding FHWs
6 Mbamara et al. (2011) ‘Knowledge, Attitude and Practice of Cervical Cancer
Screening Among Women Attending Gynaecology




7 Okunowo and Smith-Okonu (2020) ‘Cervical cancer screening among urban Women in




8 Ubajaka et al. (2015) ‘Knowledge of Cervical Cancer and Practice of Pap
Smear Testing among Secondary School Teachers in
Nnewi North Local Government Area of Anambra
State, South Eastern Nigeria’
Different study population
excluding FHWs
9 Obeidat et al. (2012) ‘Awareness, practice and attitude to cervical
Papanicolaou smear among female health care
workers in Jordan: Awareness to cervical Pap smear
among health care workers’
Different study location – Not
Nigeria
10 Gebreegziabher et al. (2016) ‘Factors Affecting the Practices of Cervical Cancer
Screening among Female Nurses at Public Health
Institutions in Mekelle Town, Northern Ethiopia,
2014: A Cross-Sectional Study’
Different study location – Not
Nigeria
11 Urasa and Darj (2011) ‘Knowledge of cervical cancer and screening practices
of nurses at a regional hospital in Tanzania’
Different study location – Not
Nigeria
12 Goyal et al. (2013) ‘Knowledge, attitude and practices about cervical
cancer and screening among nursing staff in a
teaching hospital’
Different study location – Not
Nigeria
13 Silva de Brito et al. (2014) ‘Social support and cervical and breast cancer
screening practices among nurses’
Different study location – Not
Nigeria
14 Seyoum et al. (2017) ‘Utilisation of Cervical Cancer Screening and
Associated Factors among Female Health Workers
in Governmental Health Institution of Arba Minch
Town and Zuria District, Gamo Gofa Zone, Arba
Minch, Ethiopia, 2016’
Different study location – Not
Nigeria
15 Turkistanlı et al. (2003) ‘Cervical Cancer Prevention and Early Detection - The
Role of Nurses and Midwives’
Different study location – Not
Nigeria
16 Ekwunife and Lhachimi (2017) ‘Cost-effectiveness of Human Papilloma Virus (HPV)
vaccination in Nigeria: a decision analysis using
pragmatic parameter estimates for cost and
programme coverage’
Other intervention/focus on
variables not relevant to this
review.
17 Azuogu et al. (2019) ‘Appraisal of willingness to vaccinate daughters with
human papilloma virus vaccine and cervical cancer
screening uptake among mothers of adolescent
students in Abakaliki, Nigeria’
Other intervention/focus on
variables not relevant to this
review.
(Continues)
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TABLE A5 (Continued)
S/n Author-date Title Reason
18 Chigbu and Aniebue (2011) ‘The impact of community health educators on uptake
of cervical and breast cancer prevention services in
Nigeria’
Other intervention/focus on
variables not relevant to this
review.
19 Eze and Obiebi (2019) ‘Perspectives and practices of cancer screening among
workers at a tertiary health facility in Nigeria:
indications for adaptation and integration of best
practices’
Other intervention/focus on
variables not relevant to this
review.
20 Akhigbe and Omuemu (2009) ‘Knowledge, attitudes and practice of breast cancer




variables not relevant to this
review.
21 Nyengidiki et al. (2019) ‘Does introduction of user fees affect the utilisation of
cervical cancer screening services in Nigeria?’
Other intervention/focus on
variables not relevant to this
review.
22 Onyenwenyi and Mchunu (2019) ‘Primary health care workers' understanding and skills
related to cervical cancer prevention in Sango PHC
centre in south-western Nigeria: a qualitative study’
Other intervention/focus on
variables not relevant to this
review.
23 Esan et al. (2019) ‘Awareness and utilisation of cervical cancer screening
among women in an Urban area in Southwestern
Nigeria’
Multiple Publication
24 Awoyesuku et al. (2019) ‘Determinants of cervical cancer screening via Pap
smear among female staff in a tertiary hospital in
Niger-Delta of Nigeria’
Multiple publication
25 Dodo et al. (2016) Exploring the Barriers to Breast and Cervical Cancer
Screening in Nigeria: A Narrative Review
Review – only primary studies
were considered for this
paper.
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TABLE A6 The AXIS quality assessment tool for cross-sectional studies. Link to quality assessment outcome for included studies: Critical
appraisal
Question Yes No Don't know/comment
Introduction
1 Were the aims/objectives of the study clear?
Methods
2 Was the study design appropriate for the stated
aim(s)?
3 Was the sample size justified?
4 Was the target/reference population clearly
defined? (Is it clear who the research was
about?)
5 Was the sample frame taken from an appropriate
population base so that it closely represented
the target/reference population under
investigation?
6 Was the selection process likely to select subjects/
participants that were representative of the
target/reference population under investigation?
7 Were measures undertaken to address and
categorise non-responders?
8 Were the risk factor and outcome variables
measured appropriate to the aims of the study?
9 Were the risk factor and outcome variables
measured correctly using instruments/
measurements that had been trialled, piloted or
published previously?
10 Is it clear what was used to determined statistical
significance and/or precision estimates? (e.g. p-
values, confidence intervals)
11 Were the methods (including statistical methods)
sufficiently described to enable them to be
repeated?
Results
12 Were the basic data adequately described?
13 Does the response rate raise concerns about non-
response bias?
14 If appropriate, was information about non-
responders described?
15 Were the results internally consistent?
16 Were the results presented for all the analyses
described in the methods?
Discussion
17 Were the authors' discussions and conclusions
justified by the results?
18 Were the limitations of the study discussed?
Other
19 Were there any funding sources or conflicts of
interest that may affect the authors'
interpretation of the results?
20 Was ethical approval or consent of participants
attained?
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TABLE A7 Data extraction tool. Link to data extraction
document: Data extraction
S/n Stage of the process Information available
Author(s), publication year






Main outcome measures related to cervical
cancer screening
E.g., Knowledge, attitude, practices, barriers,
facilitators, etc.
Findings
Conclusion (main recommendations for
practice or future research)
Strengths/limitations
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